The expression levels of EGF-EGFR-RAS signaling marker genes EGF, EGFR, HRAS, RASSF1 and STK4 in the HLX22 and HLX02 combination-treated cells decreased, suggesting that HLX22 in combination with HLX02 inhibited EGF-EGFR-RAS signaling to suppress tumor proliferation, survival, and invasion (Fig. 6b). This evidence concerns the gene EGF and neoplasm.